Communiqués Acrivon Therapeutics, Inc.

Actions

ACRV

US0048901096

Temps réel estimé Cboe BZX Autres places de cotation 20:54:56 16/07/2024			Varia. 5j.	Varia. 1 janv.
7,915 ^USD	+5,96 %		+10,17 %	+59,65 %

14/05	Acrivon Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
29/04	ACRIVON THERAPEUTICS, INC. : Ladenburg Thalmann maintient sa recommandation neutre	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Acrivon Therapeutics : Submission of Matters to a Vote of Security Holders Form 8 K	21/06	PU
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference	29/05	GL
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	14/05	GL
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event	24/04	GL
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316	17/04	GL
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368	10/04	GL
Acrivon Therapeutics Announces $130 Million Private Placement Financing	09/04	GL
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	28/03	GL
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316	05/03	GL
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors	04/03	GL
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors	04/03	AQ
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference	27/02	GL
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors	08/02	GL
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02	GL
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	12/01	GL
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	04/01	GL
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	04/01	AQ
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer	03/01	GL
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer	28/11	GL
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer	28/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Acrivon Therapeutics, Inc.

Actions

ACRV

US0048901096

Communiqués

Filtres